Outputs
A standardised observational framework to characterise dengue clinical epidemiology and address critical knowledge gaps to improve patient outcomes.
Latest published work and other ISARIC outputs
You can use the tools below to filter documents and other materials by category. If you have questions about access to documents or citing our research, please contact us.
CEPI and ISARIC trial collaboration overview
Vision / Objectives of the collaboration: Both CEPI and ISARIC aim to prevent illness and deaths from infectious diseases outbreaks, through research and capacity development. Objectives of the collaboration: To add value to CEPI and ISARIC efforts to enhance and protect global health by identifying and supporting synergies between Tx and Vx development, equitable access and use To work collaboratively to support the development of partners capabilities and impact, and to minimise ... Learn more
Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study
Adults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid). However, existing evidence is scarce, partly due to a lack of a standardised case definition, short follow up duration, and heterogenous study designs, resulting in wide variation of reported outcomes. The primary aim of this study was to characterise risk factors for PCC and longitudinal rates of recovery in a cohort of children and young people using a standardised protocol. Learn more
Final Report – Analysis of a Clinical Trial: Ribavirin and The Treatment Of Lassa Fever
This is a copy of the Report Analysis of a Clinical Trial for Ribavirin and the Treatment of Lassa Fever. The data were collected by the US Centers for Disease Control under their IND 17186. Learn more
Systematic Review of Scales for Measuring Infectious Disease-Related Stigma
Infectious disease outbreaks are associated with substantial stigma, which can have negative effects on affected persons and communities and on outbreak control. Thus, measuring stigma in a standardized and validated manner early in an outbreak is critical to disease control. We reviewed existing scales used to assess stigma during outbreaks. Our findings show that many different scales have been developed, but few have been used more than once, have been adequately validated, or have been ... Learn more
Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19
Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies. Learn more
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospectve multinational observational study
The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Learn more
The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): a case study of bubonic plague
Among the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics for Neglected Tropical Diseases (NTDs) and diseases affecting the most vulnerable populations. Here we explore the impact of the pandemic on a clinical trial for plague therapeutics and strategies that have been considered to ensure research efforts continue. Learn more
Clinical characterization of Lassa fever: a systematic review of clinical reports and research to inform clinical trial design
Research is urgently needed to reduce the morbidity and mortality of Lassa fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of the only current treatment recommendation, ribavirin, which has a weak clinical evidence base. To help establish a basis for the development of an adaptable, standardised clinical trial methodology, we conducted a systematic review to identify the clinical characteristics and outcomes of LF and describe how LF has ... Learn more
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: A prospective, multicentre cohort study
COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections ... Learn more
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19
The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Learn more
Evaluating clinical characteristics studies produced early in the Covid-19 pandemic:a systematic review
Clinical characterisation studies have been essential in helping inform research, diagnosis and clinical management efforts, particularly early in a pandemic. This systematic review summarises the early literature on clinical characteristics of patients admitted to hospital, and evaluates the quality of evidence produced during the initial stages of the pandemic. Learn more
Nipah virus disease: what can we do to improve patient care?
We propose a regionally led, patient-centred, and public health-centred, end-to-end framework that articulates a public health vision and a roadmap for research, development, manufacturing, and access towards the goal of improving patient outcomes. This framework includes co-creating a regulatory-compliant, clinically meaningful, and context-specific clinical development plan and establishing quality standards in clinical care and research capabilities at sites where the disease occurs. The Learn more
Research priorities for Long Covid: refined through an international multi-stakeholder forum
Learn more